Carlos Alberto Tagliati

Dr. Carlos Alberto Tagliati


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CFC.A.O. Féres
C.A.O. Féres
RMR.C. Madalosso
R.C. Madalosso
ORO.A. Rocha
O.A. Rocha
JLJoão Paulo Viana Leite
João Paulo Viana Leite
TGT.M.D.P. Guimarães
T.M.D.P. Guimarães
CTCarlos Alberto Tagliati
Carlos Alberto Tagliati

1 September 2004 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
RJR.M Jorge
R.M Jorge
JLJoão Paulo Viana Leite
João Paulo Viana Leite
AOA.B Oliveira
A.B Oliveira
CTCarlos Alberto Tagliati
Carlos Alberto Tagliati

1 January 2020 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
DTD.R. Tonholo
D.R. Tonholo
VMV.G. Maltarollo
V.G. Maltarollo
TKT. Kronenberger
T. Kronenberger
ISI.R. Silva
I.R. Silva
PAP.O. Azevedo
P.O. Azevedo
CTCarlos Alberto Tagliati
Carlos Alberto Tagliati

11 February 2014 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
MVManuela de Lima Toccafondo Vieira
Manuela de Lima Toccafondo Vieira
CTCarlos Alberto Tagliati
Carlos Alberto Tagliati
Impaired bile formation leads to the accumulation of cytotoxic bile salts in hepatocytes and, consequently, cholestasis and severe liver disease. Knowledge of the role of hepatobiliary transporters, especially the bile salt export pump (BSEP), in the pathogenesis of cholestasis is continuously increasing. This review provides an introduction into the role of these transport proteins in bile formation. It addresses the clinical relevance and pathophysiologic consequences of altered functions of these transporters by genetic mutations and drugs. In particular, the current practical aspects of identification and mitigation of drug candidates with liver liabilities employed during drug development, with an emphasis on preclinical screening for BSEP interaction, are discussed. Within the potential pathogenetic mechanisms of acquired cholestasis, the inhibition of BSEP by drugs is well established. Interference of a new compound with BSEP transport activity should raise a warning sign to conduct follow-up experiments and to monitor liver function during clinical development. A combination of in vitro screening for transport interaction, in silico predicting models, and consideration of physicochemical and metabolic properties should lead to a more efficient screening of potential liver liability.

1 August 2004 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
LSL.H. Santos
L.H. Santos
CFC.A.O. Feres
C.A.O. Feres
FMF.H. Melo
F.H. Melo
MCM.M. Coelho
M.M. Coelho
MNM.S. Nothenberg
M.S. Nothenberg
CTCarlos Alberto Tagliati
Carlos Alberto Tagliati
We investigated the anti-inflammatory, antinociceptive and ulcerogenic activity of a zinc-diclofenac complex (5.5 or 11 mg/kg) in male Wistar rats (180-300 g, N = 6) and compared it to free diclofenac (5 or 10 mg/kg) and to the combination of diclofenac (5 or 10 mg/kg) and zinc acetate (1.68 or 3.5 mg/kg). The carrageenin-induced paw edema and the cotton pellet-induced granulomatous tissue formation models were used to assess the anti-inflammatory activity, and the Hargreaves model of thermal hyperalgesia was used to assess the antinociceptive activity. To investigate the effect of orally or intraperitoneally (ip) administered drugs on cold-induced gastric lesions, single doses were administered before exposing the animals to a freezer (-18 degrees C) for 45 min in individual cages. We also evaluated the gastric lesions induced by multiple doses of the drugs. Diclofenac plus zinc complex had the same anti-inflammatory and antinociceptive effects as diclofenac alone. Gastric lesions induced by a single dose administered per os and ip were reduced in the group treated with zinc-diclofenac when compared to the groups treated with free diclofenac or diclofenac plus zinc acetate. In the multiple dose treatment, the complex induced a lower number of the most severe lesions when compared to free diclofenac and diclofenac plus zinc acetate. In conclusion, the present study demonstrates that the zinc-diclofenac complex may represent an important therapeutic alternative for the treatment of rheumatic and inflammatory conditions, as its use may be associated with a reduced incidence of gastric lesions.

10 September 2018 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
PAPatrick O. Azevedo
Patrick O. Azevedo
APAna E. Paiva
Ana E. Paiva
GSGabryella S. P. Santos
Gabryella S. P. Santos
LLLuiza Lousado
Luiza Lousado
JAJulia P. Andreotti
Julia P. Andreotti
Alexander BirbrairAlexander Birbrair
Alexander Birbrair